Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease (AMBAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01561053
Recruitment Status : Completed
First Posted : March 22, 2012
Results First Posted : July 31, 2019
Last Update Posted : July 31, 2019
Sponsor:
Collaborator:
Grifols Biologicals, LLC
Information provided by (Responsible Party):
Grifols Biologicals, LLC ( Instituto Grifols, S.A. )

Brief Summary:
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Biological: Albumin 5% Biological: Albumin 20% Biological: Immunoglobulin Phase 2 Phase 3

Detailed Description:
A clinical trial comprised of 350 subjects with probable mild to moderate Alzheimer's Disease (AD) will be conducted primarily to determine whether plasmapheresis with infusion of human albumin combined with intravenous immunoglobulin (IVIG) is able to modify patient's cognitive, functional, behavioral and global domains. There will be 3 treatment groups and 1 control group. The subjects will be randomized in a 1:1:1:1 proportion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 347 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate Alzheimer's Disease
Actual Study Start Date : April 19, 2012
Actual Primary Completion Date : March 6, 2018
Actual Study Completion Date : March 6, 2018


Arm Intervention/treatment
Experimental: High Albumin + Immunoglobulin
Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
Biological: Albumin 5%
Therapeutic plasma exchange with human albumin 5%
Other Names:
  • Albutein® 5%
  • Human Albumin Grifols 5%

Biological: Albumin 20%
Low volume plasma exchange with human albumin 5%
Other Names:
  • Albutein® 20%
  • Human Albumin Grifols 20%

Biological: Immunoglobulin
Intravenous human immunoglobulin 5%
Other Name: Flebogamma® 5% DIF

Experimental: Low Albumin + Immunoglobulin
Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
Biological: Albumin 5%
Therapeutic plasma exchange with human albumin 5%
Other Names:
  • Albutein® 5%
  • Human Albumin Grifols 5%

Biological: Albumin 20%
Low volume plasma exchange with human albumin 5%
Other Names:
  • Albutein® 20%
  • Human Albumin Grifols 20%

Biological: Immunoglobulin
Intravenous human immunoglobulin 5%
Other Name: Flebogamma® 5% DIF

Experimental: Low Albumin
Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
Biological: Albumin 5%
Therapeutic plasma exchange with human albumin 5%
Other Names:
  • Albutein® 5%
  • Human Albumin Grifols 5%

Biological: Albumin 20%
Low volume plasma exchange with human albumin 5%
Other Names:
  • Albutein® 20%
  • Human Albumin Grifols 20%

No Intervention: Control (sham) group
Simulated plasma exchange procedure



Primary Outcome Measures :
  1. Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score (Changes From Baseline to 14 Months) [ Time Frame: Baseline and 14 months ]

    ADAS-Cog total score as a change from baseline to 14 months

    The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment.


  2. Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score (Changes From Baseline to 14 Months) [ Time Frame: Baseline and 14 Months ]

    ADCS-ADL total score as a change from baseline to 14 months

    The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).



Other Outcome Measures:
  1. ADAS-Cog Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:22-26 [ Time Frame: Baseline and 14 months ]

    ADAS-Cog total score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):22-26

    The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment.


  2. ADCS-ADL Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:22-26 [ Time Frame: Baseline and 14 months ]

    ADCS-ADL total score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):22-26

    The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).


  3. ADAS-Cog Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:18-21 [ Time Frame: Baseline and 14 months ]

    ADAS-Cog score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):18-21

    The ADAS-Cog Scale is a questionnaire that assesses cognitive performance in 12 different domains. The domains are: word recall, commands, constructional praxis, delayed word-recall task, naming objects/figures, ideational praxis, orientation, word recognition, remembering test instructions, comprehension, word finding difficulty, and spoken language ability. The total score ranges from 0-80 where a higher score indicates more cognitive impairment


  4. ADCS-ADL Total Score (Changes From Baseline to 14 Months) in Patients With Baseline MMSE:18-21 [ Time Frame: Baseline and 14 months ]

    ADCS-ADL total score as a change from baseline to 14 months in patients with baseline Mini-Mental State Examination (MMSE):18-21

    The ADCS-ADL comprises 23 questions covering a wide array of activities of daily living. Many of the activities begin with an assessment of whether that activity is relevant and then, if yes, follow with an assessment of the difficulty. The total score over all activities ranges from 0-78 where a higher score indicates more autonomy (better outcome).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Males or females between 55-85 years of age at the time of signing of the informed consent document.
  2. A diagnosis of Alzheimer's disease (NINCDS-ADRDA criterion), and mini-mental status examination (MMSE) score between >/=18 and </=26.
  3. Current stable treatment with acetylcholine esterase inhibitors (AChEIs) and/or memantine for the previous three months.
  4. The patient and a close relative or the legal representative must read the patient information sheet, agree to participation in the trial, and then sign the informed consent document (the patient personally and the close relative/legal representative).
  5. The patient must be able to follow the study protocol, receive the treatment in the established time period, and continue during the follow-up interval.
  6. A brain computed axial tomography (CAT) or magnetic resonance imaging (MRI) study, obtained in the 12 months prior to recruitment, showing the absence of cerebrovascular disease, should be available. Nevertheless, it is mandatory to use the MRI obtained during the screening period to rule out any cerebrovascular disease.
  7. A stable care taker must be available, and must attend the patient study visits.

Main Exclusion Criteria:

  1. Any contraindication for plasma exchange due to behavioral disorders or abnormal coagulation parameters, such as for example:

    • Hypocalcemia (Ca++ < 8.7 mg/dL)
    • Thrombocytopenia (<100,000/µL)
    • Fibrinogen <1.5 g/L
    • Prothrombin time (Quick) p<60% versus control (international normalized ratio (INR) >1.5)
    • Beta-blocker treatment and bradycardia <55/min
    • Treatment with angiotension-converting enzyme inhibitors (ACEIs) (increased risk of allergic reactions)
  2. Hemoglobin < 10 g/dL
  3. Difficult venous access precluding plasma exchange.
  4. A history of frequent adverse reactions (serious or otherwise) to blood products.
  5. Hypersensitivity to albumin or allergies to any of the components of Albutein.
  6. History of immunoglobulin A (IgA) deficiency.
  7. Known allergies to Flebogamma DIF components such as sorbitol.
  8. History of thromboembolic complications of intravenous immunoglobulins.
  9. Plasma creatinine > 2 mg/dl.
  10. Uncontrolled high blood pressure (systolic blood pressure of 160 mmHg or higher and/or diastolic blood pressure of 100 mmHg or higher despite treatment during the last 3 months).
  11. Liver cirrhosis or any liver problem with glutamic pyruvic transaminase (GPT) > 2.5 x upper limit of normal (ULN), or bilirubin > 2 mg/dL.
  12. Heart diseases, as evidenced by myocardial infarction, severe or unstable angina, or heart failure (New York Association Class II, III or IV) in the past 12 months.
  13. Participation in other clinical trials, or the receipt of any other investigational drug in the three months prior to the start of the study.
  14. Any condition complicating adherence to the study protocol (illness with less than one year of expected survival, known drug or alcohol abuse, etc.).
  15. Pregnant or nursing women or women not using effective contraceptive methods for at least one month after plasma exchange.
  16. Fewer than six years of education (exclusion criteria under medical criterion).
  17. Less than three months with stable treatment for behavioral disorders or insomnia.
  18. Patients being treated with anticoagulants or antiplatelet therapy (antiaggregants) should not be recruited in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561053


  Show 40 Study Locations
Sponsors and Collaborators
Instituto Grifols, S.A.
Grifols Biologicals, LLC
Investigators
Layout table for investigator information
Principal Investigator: Merce Boada Rovira, MD, PhD Fundació ACE. Barcelona. Spain
Study Chair: Antonio Páez, MD Instituto Grifols, S.A.
Study Director: Laura Núñez, BSc Instituto Grifols, S.A.
  Study Documents (Full-Text)

Documents provided by Grifols Biologicals, LLC ( Instituto Grifols, S.A. ):
Study Protocol  [PDF] February 21, 2018
Statistical Analysis Plan  [PDF] July 31, 2018


Layout table for additonal information
Responsible Party: Instituto Grifols, S.A.
ClinicalTrials.gov Identifier: NCT01561053     History of Changes
Other Study ID Numbers: IG1002
First Posted: March 22, 2012    Key Record Dates
Results First Posted: July 31, 2019
Last Update Posted: July 31, 2019
Last Verified: July 2019
Keywords provided by Grifols Biologicals, LLC ( Instituto Grifols, S.A. ):
Alzheimer's disease
Amyloid Beta (AB) peptide
Albumin
Intravenous immunoglobulin
IVIG
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Immunoglobulins
Antibodies
Immunoglobulins, Intravenous
gamma-Globulins
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs